» Articles » PMID: 29403354

Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism

Overview
Specialty Molecular Biology
Date 2018 Feb 7
PMID 29403354
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Neurodegenerative diseases (NDDs) are disorders characterized by progressive deterioration of brain structure and function. Selective neuronal populations are affected leading to symptoms which are prominently motor in amyotrophic lateral sclerosis (ALS) or Huntington's disease (HD), or cognitive in Alzheimer's disease (AD) and fronto-temporal dementia (FTD). Besides the common existence of neuronal loss, NDDs are also associated with metabolic changes such as weight gain, weight loss, loss of fat mass, as well as with altered feeding behavior. Importantly, preclinical research as well as clinical studies have demonstrated that altered energy homeostasis influences disease progression in ALS, AD and HD, suggesting that identification of the pathways leading to perturbed energy balance might provide valuable therapeutic targets Signals from both the periphery and central inputs are integrated in the hypothalamus, a major hub for the control of energy balance. Recent research identified major hypothalamic changes in multiple NDDs. Here, we review these hypothalamic alterations and seek to identify commonalities and differences in hypothalamic involvement between the different NDDs. These hypothalamic defects could be key in the development of perturbations in energy homeostasis in NDDs and further understanding of the underlying mechanisms might open up new avenues to not only treat weight loss but also to ameliorate overall neurological symptoms.

Citing Articles

Climate change's impact on the nervous system: A review study.

Sadeghi M, Ghannadi P, Lotfi A, Ashayeri H Health Promot Perspect. 2025; 14(4):336-342.

PMID: 40041730 PMC: 11873770. DOI: 10.34172/hpp.43089.


The novel estrogen receptor beta agonist EGX358 and genotype influence memory, vasomotor, and anxiety outcomes in an Alzheimer's mouse model.

Schwabe M, Fleischer A, Kuehn R, Chaudhury S, York J, Sem D Front Aging Neurosci. 2024; 16:1477045.

PMID: 39629477 PMC: 11613887. DOI: 10.3389/fnagi.2024.1477045.


Age- and sex-associated alterations in hypothalamic mitochondrial bioenergetics and inflammatory-associated signaling in the 3xTg mouse model of Alzheimer's disease.

Adlimoghaddam A, Fontaine K, Albensi B Biol Sex Differ. 2024; 15(1):95.

PMID: 39587693 PMC: 11587679. DOI: 10.1186/s13293-024-00671-7.


High-resolution segmentations of the hypothalamus and its subregions for training of segmentation models.

Rodrigues L, Bocchetta M, Puonti O, Greve D, Londe A, Franca M Sci Data. 2024; 11(1):940.

PMID: 39198456 PMC: 11358401. DOI: 10.1038/s41597-024-03775-2.


The therapeutic implications of all-in-one AAV-delivered epigenome-editing platform in neurodegenerative disorders.

Kantor B, ODonovan B, Rittiner J, Hodgson D, Lindner N, Guerrero S Nat Commun. 2024; 15(1):7259.

PMID: 39179542 PMC: 11344155. DOI: 10.1038/s41467-024-50515-6.


References
1.
Steculorum S, Solas M, Bruning J . The paradox of neuronal insulin action and resistance in the development of aging-associated diseases. Alzheimers Dement. 2014; 10(1 Suppl):S3-11. DOI: 10.1016/j.jalz.2013.12.008. View

2.
Querfurth H, LaFerla F . Alzheimer's disease. N Engl J Med. 2010; 362(4):329-44. DOI: 10.1056/NEJMra0909142. View

3.
Zhao W, De Felice F, Fernandez S, Chen H, Lambert M, Quon M . Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J. 2007; 22(1):246-60. DOI: 10.1096/fj.06-7703com. View

4.
Heneka M, Carson M, El Khoury J, Landreth G, Brosseron F, Feinstein D . Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015; 14(4):388-405. PMC: 5909703. DOI: 10.1016/S1474-4422(15)70016-5. View

5.
Zhao N, Liu C, Van Ingelgom A, Martens Y, Linares C, Knight J . Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes. Neuron. 2017; 96(1):115-129.e5. PMC: 5621659. DOI: 10.1016/j.neuron.2017.09.003. View